A CAR-T cell therapy from Wugen received FDA Breakthrough Therapy designation, according to reports from Washington University School of Medicine in St. Louis. The program is focused on a cell-based immunotherapy approach aimed at targeting a defined antigen in cancer settings. Breakthrough Therapy designation provides enhanced FDA guidance and intensive involvement designed to accelerate development and review timelines for treatments showing preliminary clinical evidence. For Wugen and partners, the designation can improve the probability of faster clinical readouts and more efficient regulatory planning as trial designs move toward pivotal data packages.